Grzegorzewska Alicja E, Niepolski Leszek
Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Katedra i Klinika Nefrologii, Transplantologii i Chorób Wewnetrznych.
Pol Merkur Lekarski. 2012 Apr;32(190):260-2.
This review is focused on results of application of calcimimetic drug--cinacalcet in the treatment of secondary hyperparathyroidism in patients in 3-5 stage chronic kidney disease (CKD), excluding dialysis patients (stage 5D CKD). Oral administration of cinacalcet (15-180 mg/day) significantly reduced plasma parathormone (PTH) concentrations (> or = 30% as compared to the baseline values), but simultaneously side effects occurred, among them hypocalcemia and hyperphosphatemia. Hypocalcemia was a reason for cinacalcet withdrawal in 2-15% of patients. There is a lack of studies showing the influence of advantages and disadvantages of long-term administration of cinacalcet on outcome of 3-5 stage CKD patients.
本综述聚焦于拟钙剂西那卡塞在治疗3-5期慢性肾脏病（CKD）患者继发性甲状旁腺功能亢进中的应用结果，不包括透析患者（5D期CKD）。口服西那卡塞（15-180毫克/天）可显著降低血浆甲状旁腺激素（PTH）浓度（与基线值相比降低≥30%），但同时会出现副作用，其中包括低钙血症和高磷血症。低钙血症是2%-15%的患者停用西那卡塞的原因。目前缺乏研究表明长期服用西那卡塞的利弊对3-5期CKD患者预后的影响。
